SYBU

Across TCGA pan-cancer cohorts, SYBU mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SYBU data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SYBU mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SYBU expression acts as an unfavorable survival marker, although some lineages such as UCEC and HNSC show a favorable association.

CCRCC, UCEC, and HNSC are the cancer types where SYBU mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	III,IV	0.568	1.000	.005	36	view →
UCEC	OS	Median	All	1.000	0.930	.037	2	view →
HNSC	DFS	Quartile	All	0.735	0.368	.042	2	view →
LSCC	OS	Median	All	1.000	0.775	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SYBU–CCRCC (OS)

Open the CCRCC breakdown →